Virus status of clinical trial BE-CAR7-T cells & post stem cell transplantation outcomes

Описание: Gist: Viral reactivation is also a major concern in the immunotherapeutic approach especially after lymphodepletion, a treatment after which immune system of the patient is weak. Viral activation in this clinical trial is shown in the patients after 14 days and being controlled by the anti-viral therapy until allogenic stem cell transplantation to rebuild the immunity (figure 3a). Neutrophils and lymphocytes count also increases after allogenic stem cell transplantation (figure 3b, c). Afterwards survival statistics shows that 75% survival rate of the patients underwent this clinical trial (figure 3d). Relapse of the Refractory T-Cell also monitored and around 35% of the patients shows relapsed of the refractory T cells ALL within 36 months (figure 3e). Swimmer plots provide information about the individual timeline of the patients underwent clinical trial which indicates around 6 out of 9 have complete remission of tumor or refractory T cells ALL.
]
#cancertreatment #cancer #cancerawareness #cartcells #cartherapy #cartadvancement #clinicaltrials #cd7positivetumor #offtheshelfdesignersarees #biology #immuneresponse #immunesystem #GVHD #immunogenicresponse #tcralphabeta #cd52 #immunityrebuild #clinicaltrials #cytokinereleasesyndrome #CRS #cytokines #syndrome #virus #antivirustherapy

Reference:
https://www.nejm.org/doi/10.1056/NEJM...